A Phase I, Open-label, Multi-center, First in Human, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of MRG002 in Patients With HER2 Positive Advanced Solid Tumors
Latest Information Update: 06 Dec 2023
At a glance
- Drugs MRG 002 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Miracogen
- 02 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Oct 2022.
- 02 Dec 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Oct 2022.
- 05 Jul 2021 New trial record